Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

$60 Billion by 2015.[3]

References:

  1. Report by the Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, June 2011
  2. Report by the Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, June 2011
  3. Global Industry Analysts Inc. 2010, Pain Management: A Global Strategic Business Report.

http://www.strategyr.com/Pain_Management_Market_Report.asp

About Convergence Pharmaceuticals

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, led by CEO Clive Dix, was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline ("GSK").

Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels. There are two molecules in its development portfolio for the treatment of chronic pain, CNV1014802 which is in Phase II development for the treatment of lumbosacral radiculopathy (LSR) and CNV2197944 which is in Phase I development. Clinical Development activities for CNV2197944 are being conducted by Convergence Pharmaceuticals Ltd on behalf of Calchan Ltd.

Convergence Pharmaceuticals is well funded and raised $35.4 million in Series A financing from a syndicate of leading European and US financial institutions. For more information please go to the Company's website at http://www.convergencepharma.com

For more information about Convergence Pharmaceu
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... SAN DIEGO , March 26, 2015  BioNano ... the appointment of  Terry Salyer as chief commercial ... building highly effective, worldwide sales teams in life sciences. ... Irys ® System, a genome-mapping platform to assemble ... and investigate structural variations. To date, 32 institutions located ...
(Date:3/26/2015)... March 26, 2015 "In America," the popular ... United States that is hosted by legendary film actor James ... of botany in an upcoming segment. , Botany is ... reality it is actually quite a bit more complicated than ... different types of living organisms, from the smallest bacteria known ...
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... March 25, 2015 Accelovance, a therapeutically focused ... for "Best Contract Research Organization" at the upcoming Vaccine ... Congress. This is the eighth consecutive ... the award, winning for "Best Contract Research Organization" in ... distinction in 2013. "We,re excited to be ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... NEW BRUNSWICK, N.J., Dec. 5 Senesco Technologies, Inc. ... today that its Development and License Agreement with the ... mutual agreement because of Harris Moran,s recently announced corporate ... Harris Moran has reported that its parent company, Limagrain, ...
... BioCryst Pharmaceuticals (Nasdaq: BCRX ) announced today ... and BCX-4208, and clinical data on BCX-4208 at the 50th ... held in San Francisco, CA from December 6-9, 2008. ... inhibitors. , , The schedule ...
... YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, ... and commercializes differentiated products for patients worldwide, ... licensee of nimotuzumab from YM,s subsidiary, CIMYM ... the European Medicines Agency (EMEA) for marketing ...
Cached Biology Technology:Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 3YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 2YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 3
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
(Date:3/2/2015)... 2015  Businesses have a new option for ... Rankins Enterprises has announced the launch of a ... for businesses to protect their customers, personal data, ... Beconux is a biometric transaction processing system ... to an ATM machine, the new system fuses ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... of California, Berkeley, virologist and an assistant professor in the ... M. Keck Foundation grant, an award given to innovative young ... which totals up to $1 million over five years, will ... herpesvirus as a tool to study the inner workings of ...
... WORCESTER, Mass.In recent years, a class of small molecules known ... in regulating gene products in most animal and plant species. ... development of alcohol tolerance, a hallmark of alcohol abuse and ... and Alcoholism (NIAAA) report the findings in the July 31 ...
... death but now a study of brain tissue collected during ... and suicide. The international research group, led by Dr. ... of Western Ontario and Dr. Hymie Anisman of the Neuroscience ... that proteins that modify DNA directly are more highly expressed ...
Cached Biology News:UC Berkeley virologist named Keck Distinguished Young Scholar 2MicroRNA implicated as molecular factor in alcohol tolerance 2Study identifies changes to DNA in major depression and suicide 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
Biology Products: